The gut microbiome and metabolome associate with Schistosoma mansoni infection and cardiovascular disease risk in UgandaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This cross-sectional study asked whether the gut microbiome and metabolome help explain why Schistosoma mansoni infection is linked to lower cardiovascular disease risk. Researchers profiled stool from Ugandans in communities with high and low infection burden. They used 16S rRNA gene sequencing for bacteria and liquid chromatography-mass spectrometry for faecal metabolites. Statistical mediation, regression, and integrated microbe-metabolite network analyses linked infection, gut features, and cardiometabolic risk factors.
Who was studied?
The cohort was 209 people living in Uganda, drawn from a rural Lake Victoria fishing-island trial and a parallel urban Entebbe survey. Infection was confirmed by both Kato-Katz microscopy and PCR. 128 participants (61.2%) were S. mansoni positive and 81 (38.8%) negative. There were 108 males and 101 females, spanning ages 10 to 40 and older. All had complete lipid and blood pressure data. The design was observational and cannot establish causation.
What were the most important findings?
S. mansoni infection was associated with higher gut alpha diversity (Shannon p equals 0.048, observed richness p equals 0.008). Urban infected and uninfected communities separated in structure (PERMANOVA p equals 0.011), but rural did not. Infection enriched taxa including Treponema and depleted Prevotella and Streptococcus. Several infection-linked taxa statistically mediated reductions in LDL cholesterol, total cholesterol, systolic blood pressure, glucose, and insulin. Elevated metabolites in infected people were enriched for LXR-regulated lipid pathways (all p equals 0.0003), including cholesterol transport and bile acid homeostasis.
What are the greatest implications of this study?
The findings suggest part of schistosomiasis's apparent cardiovascular benefit may run through gut microbiome and metabolite changes, not immune effects alone. Infection-linked taxa and lipid-signalling metabolites tracked with lower LDL cholesterol and blood pressure. The authors stress this is a cross-sectional association, so causation cannot be inferred. Diet and antibiotic use were incompletely measured. Helminths can also harm the heart via egg-driven inflammation. The work identifies candidate microbial pathways for future mechanistic and interventional study.